Harbin Veterinary Research InstituteHarbin Veterinary Research Institute

Publications

2024

  1. Gu C, Maemura T, Guan L, Eisfeld AJ, Biswas A, Kiso M, Uraki R, Ito M, Trifkovic S, Wang T, Babujee L, Presler R Jr, Dahn R, Suzuki Y, Halfmann PJ, Yamayoshi S, Neumann G, Kawaoka Y. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature, in press. doi: 10.1038/s41586-024-08254-7.
  2. Kuwata T, Kaku Y, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Uraki R, Okazaki K, Minami R, Nagasaki Y, Nagashima M, Yoshida I, Sadamasu K, Yoshimura K, Ito M, Kiso M, Yamayoshi S, Imai M, Ikeda T, Sato K, Toyoda M, Ueno T, Inoue T, Tanaka Y, Kimura KT, Hashiguchi T, Sugita Y, Noda T, Morioka H, Kawaoka Y, Matsushita S; Genotype to Phenotype Japan (G2P-Japan) Consortium. Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case. EBioMedicine, in press. doi: 10.1016/j.ebiom.2024.105439.
  3. Zhou NE, Tang S, Bian X, Parai MK, Krieger IV, Flores A, Jaiswal PK, Bam R, Wood JL, Shi Z, Stevens LJ, Scobey T, Diefenbacher MV, Moreira FR, Baric TJ, Acharya A, Shin J, Rathi MM, Wolff KC, Riva L, Bakowski MA, McNamara CW, Catanzaro NJ, Graham RL, Schultz DC, Cherry S, Kawaoka Y, Halfmann PJ, Baric RS, Denison MR, Sheahan TP, Sacchettini JC. An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo. Cell Rep, in press. doi: 10.1016/j.celrep.2024.114929.
  4. Chiba S, Kiso M, Yamada S, Someya K, Onodera Y, Yamaguchi A, Matsunaga S, Jounai N, Yamayoshi S, Takeshita F, Kawaoka Y. Protective effects of an mRNA vaccine candidate encoding H5HA clade 2.3.4.4b against the newly emerged dairy cattle H5N1 virus. EBioMedicine 109: 105408, 2024. doi: 10.1016/j.ebiom.2024.105408. (NOV 2024)
  5. Chiba S, Kiso M, Yamada S, Someya K, Onodera Y, Yamaguchi A, Matsunaga S, Uraki R, Iwatsuki-Horimoto K, Yamayoshi S, Takeshita F, Kawaoka Y. An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection. NPJ Vaccines 9(1): 189, 2024. doi: 10.1038/s41541-024-00988-9. (OCT 2024)
  6. Chiba S, Maemura T, Loeffler K, Frey SJ, Gu C, Biswas A, Hatta M, Kawaoka Y, Kane RS. Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity. Bioeng Transl Med 9(5): e10689, 2024. doi: 10.1002/btm2.10689. (JUN 2024)
  7. Neumann G, Kawaoka Y. Highly pathogenic H5N1 avian influenza virus outbreak in cattle: the knowns and unknowns. Nat Rev Microbiol 22, 525-526, 2024. (SEP 2024)
  8. Takashita E, Ichikawa M, Fujisaki S, Morita H, Nagata S, Miura H, Watanabe S, Hasegawa H, Kawaoka Y. Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. Int J Infect Dis 146: 107134, 2024. doi: 10.1016/j.ijid.2024.107134. (SEP 2024)
  9. Eisfeld AJ, Biswas A, Guan L, Gu C, Maemura T, Trifkovic S, Wang T, Babujee L, Dahn R, Halfmann PJ, Barnhardt T, Neumann G, Suzuki Y, Thompson A, Swinford AK, Dimitrov KM, Poulsen K, Kawaoka Y. Pathogenicity and transmissibility of bovine H5N1 influenza virus. Nature　633(8029): 426-432, 2024. doi: 10.1038/s41586-024-07766-6. (SEP 2024)
  10. Kiso M, Uraki R, Yamayoshi S, Imai M, Kawaoka Y. Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals. iScience 27(9): 110729, 2024. doi: 10.1016/j.isci.2024.110729. (AUG 2024)
  11. Maruki T, Nomoto H, Iwamoto N, Yamamoto K, Kurokawa M, Iwatsuki-Horimoto K, Yamayoshi S, Suzuki Y, Kawaoka Y, Ohmagari N. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma. J Infect Chemother 30(8): 793-795, 2024. doi: 10.1016/j.jiac.2024.01.008. (AUG 2024)
  12. Guan L, Eisfeld AJ, Pattinson D, Gu C, Biswas A, Maemura T, Trifkovic S, Babujee L, Presler R Jr, Dahn R, Halfmann PJ, Barnhardt T, Neumann G, Thompson A, Swinford AK, Dimitrov KM, Poulsen K, Kawaoka Y. Cow's milk containing avian influenza A(H5N1) virus - heat inactivation and infectivity in mice. N Engl J Med 391(1): 87-90, 2024. doi: 10.1056/NEJMc2405495. (MAY 2024)
  13. Mühlemann B, Wilks SH, Baracco L, Bekliz M, Carreño JM, Corman VM, Davis-Gardner ME, Dejnirattisai W, Diamond MS, Douek DC, Drosten C, Eckerle I, Edara VV, Ellis M, Fouchier RAM, Frieman M, Godbole S, Haagmans B, Halfmann PJ, Henry AR, Jones TC, Katzelnick LC, Kawaoka Y, Kimpel J, Krammer F, Lai L, Liu C, Lusvarghi S, Meyer B, Mongkolsapaya J, Montefiori DC, Mykytyn A, Netzl A, Pollett S, Rössler A, Screaton GR, Shen X, Sigal A, Simon V, Subramanian R, Supasa P, Suthar MS, Türeli S, Wang W, Weiss CD, Smith DJ*. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays. Sci Transl Med 16(747): eadl1722, 2024. doi: 10.1126/scitranslmed.adl1722. Epub 2024 May 15. 2024. (MAY 2024)
  14. Ueki H, Kiso M, Furusawa Y, Iida S, Yamayoshi S, Nakajima N, Imai M, Suzuki T, Kawaoka Y. Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging. Viruses 16(4): 537, 2024. doi: 10.3390/v16040537. (MAR 2024)
  15. Fukuyama S, Shoemaker JE, Zhao D, Nagajima N, Tomita Y, Maemura T, Lopes TJS, Watanabe T, Yamayoshi S, Hasegawa H, Kawaoka Y. Attenuation of A(H7N9) influenza virus infection in mice exposed to cigarette smoke. NPJ Viruses 2: 16, 2024. doi.org/10.1038/s44298-024-00026-4. (MAR 2024)
  16. Halfmann PJ, Iwatsuki-Horimoto K, Kuroda M, Hirata Y, Yamayoshi S, Iida S, Uraki R, Ito M, Ueki H, Furusawa Y, Sakai-Tagawa Y, Kiso M, Armbrust T, Spyra S, Maeda K, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. Commun Biol 7(1): 331, 2024. doi: 10.1038/s42003-024-06015-w. (MAR 2024)
  17. Guan L, Babujee L, Presler R, Pattinson D, Nguyen HLK, Hoang VMP, Le MQ, Bakel HV, Kawaoka Y, Neumann G. Avian H6 Influenza Viruses in Vietnamese Live Bird Markets during 2018-2021. Viruses 16(3): 367, 2024. doi: 10.3390/v16030367. (FEB 2024)
  18. Halfmann PJ, Loeffler K, Duffy A, Kuroda M, Yang JE, Wright ER, Kawaoka Y, Kane RS. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nat Commun 15(1): 1284, 2024. doi: 10.1038/s41467-024-45495-6. (FEB 2024)
  19. Gu C, Fan S, Dahn R, Babujee L, Chiba S, Guan L, Maemura T, Pattinson D, Neumann G, Kawaoka Y. Characterization of a human H3N8 influenza virus. EBioMedicine 101: 105034, 2024. doi: 10.1016/j.ebiom.2024.105034. (FEB 2024)
  20. Yamayoshi S, Nagai E, Mitamura K, Hagihara M, Kobayashi R, Takahashi S, Shibata A, Uwamino Y, Hasegawa N, Iqbal A, Kamimaki I, Iwatsuki-Horimoto K, Nagamura-Inoue T, Kawaoka Y.　Seroprevalence of SARS-CoV-2 N antibodies between December 2021 and March 2023 in Japan.　Epidemiol Infect 152:e24, 2024. doi: 10.1017/S0950268824000141. (JAN 2024)
  21. Whitworth IT, Knoener RA, Puray-Chavez M, Halfmann P, Romero S, Baddouh M, Scalf M, Kawaoka Y, Kutluay SB, Smith LM, Sherer NM. Defining distinct RNA-protein interactomes of SARS-CoV-2 genomic and subgenomic RNAs. J Proteome Res23(1): 149-160, 2024. doi: 10.1021/acs.jproteome.3c00506. (JAN 2024)
  22. Uraki R, Imai M, Ito M, Yamayoshi S, Kiso M, Jounai N, Miyaji K, Iwatsuki-Horimoto K, Takeshita F, Kawaoka Y. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants. NPJ Vaccines 9(1): 4, 2024 doi: 10.1038/s41541-023-00800-0. (JAN 2024)
  23. Ishizaka A, Koga M, Mizutani T, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV. BMC Microbiol 24(1): 6, 2024. doi: 10.1186/s12866-023-03157-5. (JAN 2024)

2023

  1. Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep 42(12): 113580, 2023. doi: 10.1016/j.celrep.2023.113580. 2023. (DEC 2023)
  2. Yamayoshi S, Ito M, Iwatsuki-Horimoto K, Yasuhara A, Okuda M, Hamabata T, Murakami J, Duong C, Yamamoto T, Kuroda Y, Maeda K, Kawaoka Y. Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan, 2023. One Health 17:100588. doi: 10.1016/j.onehlt.2023.100588. 2023. (DEC 2023)
  3. Maemura T, Guan L, Gu C, Eisfeld A, Biswas A, Halfmann P, Neumann G, Kawaoka Y. Characterization of highly pathogenic clade 2.3.4.4b H5N1 mink influenza viruses. EBioMedicine 97: 104827, 2023. doi: 10.1016/j.ebiom.2023.104827. (NOV 2023)
  4. Iwatsuki-Horimoto K, Ito M, Okuda-Hamabata M, Takagi H, Imai M, Kawaoka Y. Cardiomyopathy does not exacerbate the severity of pneumonia caused by a SARS-CoV-2 delta variant in the J2N-k hamster model. Viruses 15(12): 2280, 2023. doi:org/10.3390/v15122280. (NOV 2023)
  5. Hou YJ, Chiba S, Leist SR, Meganck RM, Martinez DR, Schäfer A, Catanzaro NJ, Sontake V, West A, Edwards CE, Yount B, Lee RE, Gallant SC, Zost SJ, Powers J, Adams L, Kong EF, Mattocks M, Tata A, Randell SH, Tata PR, Halfmann P, Crowe JE Jr, Kawaoka Y, Baric RS.　Host range, transmissibility and antigenicity of a pangolin coronavirus.　Nat Microbiol 8(10): 1820-1833, 2023. doi: 10.1038/s41564-023-01476-x. (OCT 2023)
  6. Wilks SH, Mühlemann B, Shen X, Türeli S, LeGresley EB, Netzl A, Caniza MA, Chacaltana-Huarcaya JN, Corman VM, Daniell X, Datto MB, Dawood FS, Denny TN, Drosten C, Fouchier RAM, Garcia PJ, Halfmann PJ, Jassem A, Jeworowski LM, Jones TC, Kawaoka Y, Krammer F, McDanal C, Pajon R, Simon V, Stockwell MS, Tang H, van Bakel H, Veguilla V, Webby R, Montefiori DC, Smith DJ. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382(6666): eadj0070, 2023. doi: 10.1126/science.adj0070. (OCT 2023)
  7. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate. iScience 26(11): 108147, 2023. doi: 10.1016/j.isci.2023.108147. (OCT 2023)
  8. Chiba S, Halfmann PJ, Iida S, Hirata Y, Sato Y, Kuroda M, Armbrust T, Spyra S, Suzuki T, Kawaoka Y. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2. Vaccine 41(41): 6025-6035, 2023. doi: 10.1016/j.vaccine.2023.08.054. (SEP 2023)
  9. Guan L, Babujee L, Browning VL, Presler R, Pattinson D, Nguyen HLK, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Continued circulation of highly pathogenic H5 influenza viruses in Vietnamese live bird markets in 2018-2021. Viruses 15(7): 1596, 2023. doi: 10.3390/v15071596. (JUL 2023)
  10. Chiba S, Kong H, Neumann G, Kawaoka Y. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes. mBio 14(4): e0062223, 2023. doi: 10.1128/mbio.00622-23. 2023. (JUL 2023)
  11. Muramoto Y, Takahashi S, Halfmann PJ, Gotoh S, Noda T, Kawaoka Y. Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures. Lancet Microbe 4(7): e486, 2023. doi: 10.1016/S2666-5247(23)00100-3. (JUL 2023)
  12. Halfmann PJ, Uraki R, Kuroda M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Kawaoka Y. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. EBioMedicine 93:104677, 2023. doi: 10.1016/j.ebiom.2023.104677. 2023. (JUL 2023)
  13. Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun 14(1): 3952, 2023. doi: 10.1038/s41467-023-39704-x. 2023. (JUL 2023)
  14. Ishizaka A, Koga M, Mizutani T, Uraki R, Yamayoshi S, Iwatsuki-Horimoto K, Yamamoto S, Imai M, Tsutsumi T, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol J 20(1): 146, 2023. doi: 10.1186/s12985-023-02113-z. 2023. (JUL 2023)
  15. Kiso M, Yamayoshi S, Iida S, Furusawa Y, Hirata Y, Uraki R, Imai M, Suzuki T, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nat Commun 14(1): 4231. doi: 10.1038/s41467-023-40018-1. 2023. (JUL 2023)
  16. Kiso M, Yamayoshi S, Kawaoka Y. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors. J Antimicrob Chemother 78(7): 1649-1657, 2023. doi: 10.1093/jac/dkad145. 2023. (JUL 2023)
  17. Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. iScience 26(7): 107208, 2023. doi: 10.1016/j.isci.2023.107208. 2023. (JUN 2023)
  18. Tamura D, Kawaoka Y. Omicron proliferation in the nasal cavity may explain its high infectivity. J Infect 86(6): 584-587, 2023. doi: 10.1016/j.jinf.2023.03.006. 2023. (JUN 2023)
  19. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate. Lancet Reg Health West Pac 34: 100777, 2023. doi: 10.1016/j.lanwpc.2023.100777. 2023. (MAY 2023)
  20. Furusawa Y, Kiso M, Iida S, Uraki R, Hirata Y, Imai M, Suzuki T, Yamayoshi S, Kawaoka Y.　In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters.　EBioMedicine 91:104561, 2023. doi: 10.1016/j.ebiom.2023.104561. 2023. (MAY 2023)
  21. Sakai-Tagawa Y, Yamayoshi S, Halfmann PJ, Wilson N, Bobholz M, Vuyk WC, Wei W, Ries H, O'Connor DH, Friedrich TC, Sordillo EM, van Bakel H, Simon V, Kawaoka Y. Sensitivity of rapid antigen tests for Omicron subvariants of SARS-CoV-2. J Med Virol 95(5): e28788, 2023. doi: 10.1002/jmv.28788. 2023. (MAY 2023)
  22. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1. Lancet Infect Dis 23(5): 525-526, 2023. doi: 10.1016/S1473-3099(23)00132-9. 2023. (MAY 2023)
  23. Guan L, Zhong G, Fan S, Plisch EM, Presler R, Gu C, Babujee L, Pattinson D, Le Khanh Nguyen H, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Highly Pathogenic H5 Influenza Viruses Isolated between 2016 and 2017 in Vietnamese Live Bird Markets. Viruses. 15(5):1093, 2023. doi: 10.3390/v15051093. 2023. (APR 2023)
  24. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann P, Pekosz A, Kawaoka Y. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Inf Dis 23(4): 402-403, 2023. doi: 10.1016/S1473-3099(23)00070-1. 2023. (APR 2023)
  25. Changrob S, Halfmann PJ, Liu H, Torres JL, McGrath JJC, Ozorowski G, Li L, Wilbanks GD, Kuroda M, Maemura T, Huang M, Zheng NY, Turner HL, Erickson SA, Fu Y, Yasuhara A, Singh G, Monahan B, Mauldin J, Srivastava K, Simon V, Krammer F, Sather DN, Ward AB, Wilson IA, Kawaoka Y, Wilson PC. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct Omicron subvariants. J Clin Invest 133(8): e166844, 2023. doi: 10.1172/JCI166844. 2023. (APR 2023)
  26. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun 14(1): 1620. doi: 10.1038/s41467-023-37059-x. 2023. (MAR 2023)
  27. Furusawa Y, Yamayoshi S, Kawaoka Y. The accuracy of reverse genetics systems for SARS-CoV-2: Circular polymerase extension reaction versus bacterial artificial chromosome. Influenza Other Respir Viruses 17(3): e13109. doi: 10.1111/irv.13109. 2023. (MAR 2023)
  28. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nat Commun 14(1): 1076. doi: 10.1038/s41467-023-36729-0. 2023. (FEB 2023)
  29. Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, Kuroki H, Hayashi Y, Seki M, Kasuya N, Koga M, Adachi E, Iwatsuki-Horimoto K, Yotsuyanagi H, Yamayoshi S, Kawaoka Y. Characterization of influenza A(H1N1)pdm09 viruses isolated in the 2018-2019 and 2019-2020 influenza seasons in Japan.　Viruses 15(2): 535. doi: 10.3390/v15020535. 2023. (FEB 2023)
  30. Neumann G, Kawaoka Y. The COVID-19 pandemic-a potential role for antivirals in mitigating pandemics. Viruses 15(2): 303. doi: 10.3390/v15020303. 2023. (JAN 2023)
  31. Iwatsuki-Horimoto K, Ueki H, Ito M, Nagasawa S, Hirata Y, Hashizume K, Ushiwata K, Iwase H, Makino Y, Ushiku T, Akitomi S, Imai M, Saitoh H, Kawaoka Y. SARS-CoV-2 transmission from virus-infected dead hamsters. mSphere 8(1): e0041122. doi: 10.1128/msphere.00411-22. 2023. (FEB 2023)
  32. Koga M, Iwatsuki-Horimoto K, Kikuchi T, Yamayoshi S, Kawaoka Y, Yotsuyanagi H. Previous Omicron infection may be protective against reinfection with Omicron variant BA.5 for at least five months. Clin Microbiol Infect 29(1):120-121, 2023. doi: 10.1016/j.cmi.2022.09.009. (JAN 2023)
  33. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann P, Kawaoka Y. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med 388(1):89-91, 2023. doi: 10.1056/NEJMc2214302. (JAN 2023)
  34. Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, Otani A, Kiso M, Sakai-Tagawa Y, Ueki H, Yotsuyanagi H, Imai M, Kawaoka Y. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis 23(1):30-32, 2023. doi: 10.1016/S1473-3099(22)00816-7. (JAN 2023)
  35. Chiba S, Hatta M, Pattinson D, Yasuhara A, Neumann G, Kawaoka Y. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses. Vaccine 41(2):590-597, 2023. doi: 10.1016/j.vaccine.2022.12.005. (JAN 2023)
  36. Takashita E, Watanabe S, Hasegawa H, Kawaoka Y. Are twindemics occurring? Influenza Other Respir Viruses 17(1): e13090. doi: 10.1111/irv.13090. (JAN 2023)
  37. Neumann G, Kawaoka Y. Which virus will cause the next pandemic? Viruses 15(1): 199, 2023. doi: 10.3390/v15010199. (JAN 2023)

2022

  1. Boon ACM, Darling TL, Halfmann PJ, Franks J, Webby RJ, Barouch DH, Port JR, Munster VJ, Diamond MS, Kawaoka Y. Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. PLoS Pathog 18(12): e1010970, 2022. doi: 10.1371/journal.ppat.1010970. (DEC 2022)
  2. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612(7940):540-545, 2022. doi: 10.1038/s41586-022-05482-7. (DEC 2022)
  3. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N Engl J Med 387(22):2094-2097, 2022. doi: 10.1056/NEJMc2211845. (DEC 2022)
  4. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yomayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/imdevimab for active COVID-19 pneumonia persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy. Jpn J Infect Dis 75(6): 608-611, 2023. doi: 10.7883/yoken.JJID.2022.092. (NOV 2022)
  5. Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y. Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020窶溺arch 2022, Japan. Emerg Infect Dis 28(11): 2198-2205, 2022. (NOV 2022)
  6. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat Commun 13(1): 6602, 2022. (NOV 2022)
  7. Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Lim LA, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y. Immunological correlates of prevention of the onset of seasonal H3N2 influenza. J Infect Dis 226(10): 1800-1808, 2022. (NOV 2022)
  8. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y. Efficacy of antiviral agents against the Omicron subvariant BA.2.75. N Engl J Med 387(13):1236-1238, 2022. (SEP 2022)
  9. Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, Takashita E, Ujie M, Furusawa Y, Yasuhara A, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Watanabe S, Hasegawa H, Kawaoka Y. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol 7(8): 1252-1258, 2022. (AUG 2022)
  10. Ueki H, Ujie M, Komori Y, Kato T, Imai M, Kawaoka Y. Effectiveness of HEPA filters at removing infectious SARS-CoV-2 from the air. mSphere 7(4): e0008622, 2022. (AUG 2022)
  11. Meng F, Yang H, Qu Z, Chen Y, Zhang Y, Zhang Y, Liu L, Zeng X, Li C, Kawaoka Y, Chen H.縲€A Eurasian avian-like H1N1 swine influenza reassortant virus became pathogenic and highly transmissible due to mutations in its PA gene. Proc Natl Acad Sci U S A 119(34): e2203919119, 2022. (AUG 2022)
  12. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 387(5):468-470, 2022. (AUG 2022)
  13. Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Sci Transl Med. eabm4908, 2022. (AUG 2022)
  14. Patania OM, Chiba S, Halfmann PJ, Hatta M, Maemura T, Bernard KA, Kawaoka Y, Crawford LK. Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats. Vet Pathol 59(4):696-706, 2022. (JUL 2022)
  15. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature 607(7917): 119-127, 2022. (JUL 2022)
  16. Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N. Parsing the role of NSP1 in SARS-CoV-2 infection. Cell Rep 39(11):110954, 2022. (JUN 2022)
  17. Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. Anti-SARS CoV-2 IgG in COVID-19 patients with hematological diseases: a single-center, retrospective study in Japan. Intern Med 61(11) :1681-1686, 2022. doi: 10.2169/internalmedicine.9209-21. (JUN 2022)
  18. Darling TL, Ying B, Whitener B, VanBlargan LA, Bricker TL, Liang CY, Joshi A, Bamunuarachchi G, Seehra K, Schmitz AJ, Halfmann PJ, Kawaoka Y, Elbashir SM, Edwards DK, Thackray LB, Diamond MS, Boon ACM. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. Med (N Y) 3(5): 309-324.e6, 2022. (MAY 2022)
  19. Halfmann PJ, Kuroda M, Maemura T, Chiba S, Armbrust T, Wright R, Balaram A, Florek KR, Bateman AC, Kawaoka Y. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. Cell Rep 39(3): 110688, 2022. (APR 2022)
  20. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med 386(15): 1475-1477, 2022. (APR 2022)
  21. Ueki H, Ito M, Furusawa Y, Yamayoshi S, Inoue SI, Kawaoka Y. A 265-nanometer high-power deep-UV light-emitting diode rapidly inactivates SARS-CoV-2 aerosols. mSphere 7: e0094121, 2022. (APR 2022)
  22. Murakami J, Shibata A, Neumann G, Imai M, Watanabe T, Kawaoka Y. Characterization of H9N2 Avian influenza viruses isolated from poultry products in a mouse model. Viruses 14: 728. 2022. (MAR 2022)
  23. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. N Engl J Med 386: 995-998, 2022. (MAR 2022)
  24. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippﾃ PE, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602(7898): 664-670, 2022. (FEB 2022)
  25. Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in syrian hamsters. J Virol 96: e01551-21, 2022. (FEB 2022)
  26. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602: 300-306, 2022. (FEB 2022)
  27. Halfmann PJ, Kuroda M, Armbrust T, Accola M, Valdez R, Kowalski-Dobson T, Rehrauer W, Gordon A, Kawaoka Y. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Rep 38: 110394, 2022. (FEB 2022)
  28. Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K, Pinto D, VanBlargan L, Marco A, Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse K, Dillen J, Powell A, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko N, Logue J, Iqbal N, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippﾃ P, Franzetti-Pellanda A, Garzoni C, Halfmann P, Kawaoka Y, Hebner C, Purcell L, Piccoli L, Pizzuto M, Walls A, Diamond M, Telenti A, Virgin H, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602: 664-670, 2022. (FEB 2022)
  29. Halfmann P, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Singh G, Foster S, Ying B, Case J, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, Henry A, Ciouderis K, Florek K, Patel M, Odle A, Wong LY, Bateman A, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche A, Sordillo E, Chang L, Bakel H, Simon V, PSP study group, Douek D, Sullivan N, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Diamond M, KawaokaY. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603: 687-692, 2022. (JAN 2022)
  30. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 19: 1-6, 2022. (JAN 2022)
  31. Ohta M, Bannai H, Kambayashi Y, Tamura N, Tsujimura K, Yamayoshi S, Kawaoka Y, Nemoto M. Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine. Equine Vet J 54: 139-144, 2022. (JAN 2022)
    32. 14:59 2023/02/01

2021

  1. Kong X, Guan L, Shi J, Kong H, Zhang Y, Zeng X, Tian G, Liu L, Li C, Kawaoka Y, Deng G, Chen H. A single-amino-acid mutation at position 225 in hemagglutinin attenuates H5N6 influenza virus in mice. Emerg Microbes Infect 10: 2052-2061, 2021. (DEC 2021)
  2. Kong H, Fan S, Takada K, Imai M, Neumann G, Kawaoka Y. H3N2 influenza viruses with 12- or 16-amino acid deletions in the receptor-binding region of their hemagglutinin protein. mBio 12: e0151221, 2021. (DEC 2021)
  3. Asaka MN, Utsumi D, Kamada H, Nagata S, Nakachi Y, Yamaguchi T, Kawaoka Y, Kuba K, Yasutomi Y. Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2 transgenic mice. JCI Insight 6(19): e152529, 2021. (OCT 2021)
  4. Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors FcﾎｳRIIA and FcﾎｳRIIIA but does not contribute to aberrant cytokine production by macrophages. mBio 12, 2021. (OCT 2021)
  5. Sakai-Tagawa Y, Yamayoshi S, Halfmann P, Kawaoka Y. Comparative sensitivity of rapid antigen tests for the Delta variant (B.1.617.2) of SARS-CoV-2. Viruses 13: 2183, 2021. (OCT 2021)
  6. Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A 118(27): e2106535118, 2021. (JUL 2021)
  7. Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai YN, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54(6): 1290-1303.e7, 2021. (JUN 2021)
  8. Saito M, Itoh Y, Yasui F, Munakata T, Yamane D, Ozawa M, Ito R, Katoh T, Ishigaki H, Nakayama M, Shichinohe S, Yamaji K, Yamamoto N, Ikejiri A, Honda T, Sanada T, Sakoda Y, Kida H, Le TQM, Kawaoka Y, Ogasawara K, Tsukiyama-Kohara K, Suga H, Kohara M. Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models. Nat Commun 12(1): 2654, 2021. (MAY 2021)
  9. Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, Yokota H, Furusawa Y, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hasegawa N, Murata M; Keio Donner Project Members. Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection. J Infect Chemother S1341-321X(21)00117-3, 2021. (APR 2021)
  10. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, Kumazaki M, Usuku S, Tanaka N, Okubo I, Morita H, Nagata S, Watanabe S, Hasegawa H, Kawaoka Y. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses 15(4): 488-494, 2021. (JUL 2021)
  11. Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, Koga M, Adachi E, Saito M, Nakachi I, Ogura T, Baba R, Ito M, Kiso M, Yasuhara A, Yamada S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Yamayoshi S, Yotsuyanagi H, Kawaoka Y, Khurana S. Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci Adv 7(10): eabf2467, 2021. (MAR 2021)
  12. Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine 32: 100734, 2021. (FEB 2021)
  13. Kong H, Burke DF, da Silva Lopes TJ, Takada K, Imai M, Zhong G, Hatta M, Fan S, Chiba S, Smith D, Neumann G, Kawaoka Y. Plasticity of the influenza virus H5 HA protein. mBio 12(1): e03324-20, 2021. (FEB 2021)
  14. Chiba S, Halfmann PJ, Hatta M, Maemura T, Fan S, Armbrust T, Swartley OM, Crawford LK, Kawaoka Y. Protective immunity and persistent lung sequelae in domestic cats after SARS-CoV-2 Infection. Emerg Infect Dis 27(2): 660-663, 2021. (FEB 2021)

2020

  1. Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Comparison of rapid antigen tests for COVID-19. Viruses 12(12): 1420, 2020. (DEC 2020)
  2. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, Schëfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370(6523):1464-1468, 2020. (DEC 2020)
  3. Ueki H, Furusawa Y, Iwatsuki-Horimoto K, Imai M, Kabata H, Nishimura H, Kawaoka Y. Effectiveness of face masks in preventing airborne transmission of SARS-CoV-2. mSphere 5:e00637-20, 2020. (OCT 2020)
  4. Fukuyama S, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Gregg RW, Katsura H, Tomita Y, Maemura T, da Silva Lopes TJ, Watanabe T, Shoemaker JE, Hasegawa H, Yamayoshi S, Kawaoka Y. Pathogenesis of influenza A(H7N9) virus in aged nonhuman primates. J Infect Dis 222(7): 1155-1164, 2020. (OCT 2020)
  5. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci USA 117(28): 16587-16595, 2020. (JUL 2020)
  6. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12(6): 629, 2020. (JUN 2020)
  7. Kiso M, Yamayoshi S, Kawaoka Y. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. Commun Biol 3(1): 219, 2020. (MAY 2020)
  8. Feng H, Nakatsu S, Lopes TJDS, Imai M, Yamayoshi S, Yamashita M, Watanabe T, Kawaoka Y. Identification of novel adjuvants for ebola virus-like particle vaccine. Vaccines (Basel) 8: E215, 2020. (MAY 2020)
  9. Kato-Miyashita, S, Sakai-Tagawa Y, Yamashita M, Iwatsuki-Horimoto K, Ito M, Tokita A, Hagiwara H, Izumida N, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Yotsuyanagi H, Kawaoka Y, Imai M. Antigenic variants of influenza B viruses isolated in Japan during the 2017窶・018 and 2018窶・019 influenza seasons. Influenza Other Respi Viruses 14: 311-319, 2020. (MAY 2020)
  10. Kiso M, Yamayoshi S, Murakami J, Kawaoka Y. Baloxavir marboxil treatment of nude mice infected with influenza A virus. J Infect Dis 221: 1699-1702, 2020. (APR 2020)
  11. Ueki H, Wang IH, Zhao D, Gunzer M, Kawaoka Y. Multicolor two-photon imaging of in vivo cellular pathophysiology upon influenza virus infection using the two-photon IMPRESS. Nat Protoc 15: 1041-1065, 2020. (MAR 2020)
  12. Wu L, Mitake H, Kiso M, Ito M, Iwatsuki-Horimoto K, Yamayoshi S, Lopes TJS, Feng H, Sumiyoshi R, Shibata A, Osaka H, Imai M, Watanabe T, Kawaoka Y. Characterization of H7N9 avian influenza viruses isolated from duck meat products. Transboundary and Emerging Diseases 67: 792-798, 2020. (MAR 2020)
  13. Maemura T, Fukuyama S, Kawaoka Y. High levels of miR-483-3p are present in serum exosomes upon infection of mice with highly pathogenic avian influenza virus. Front Microbiol 11: 144, 2020. (FEB 2020)
  14. Zhong G, Fan S, Hatta M, Nakatsu S, Walters KB, Lopes TJS, Wang JI, Ozawa M, Karasin A, Li Y, Tong S, Donis RO, Neumann G, Kawaoka Y. Mutations in the NA-like protein of bat influenza H18N11 virus enhance virus replication in mammalian cells, mice, and ferrets. J Virol 94: e01416-19, 2020. (FEB 2020)
  15. Mitake H, Yasuhara A, Lopes TJS, Tagawa-Sakai Y, Shimizu K, Ozawa H, Kawakami C, Morikawa S, Sugaya N, Watanabe T, Kawaoka Y. Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan. Viruses 12(2). pii: E155, 2020. (JAN 2020)
  16. Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M, Murakami J, Yasuhara A, Takada K, Ito M, Nakajima N, Takahashi K, Lopes TJS, Tokita A, Hagiwara H, Izumida N, Kuroki H, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Hasegawa H, Kawaoka Y. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nature Microbiology 5: 27-33, 2020. (JAN 2020)

2019

  1. Kuwahara T, Yamayoshi S, Noda T, Kawaoka Y. G protein pathway suppressor 1 promotes influenza virus polymerase activity by activating the NF-ﾎｺB signaling pathway. Mbio 10(6): e02867-19, 2019. (DEC2019)
  2. Kiso M, Yamayoshi S, Furusawa Y, Kawaoka Y. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses 11(11): 1066, 2019. (NOV 2019)
  3. Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res 171: 104591, 2019. (NOV 2019)
  4. Matsuzawa Y, Iwatsuki-Horimoto K, Nishimoto Y, Abe Y, Fukuyama S, Hamabata T, Okuda M, Go Y, Watanabe T, Imai M, Arai Y, Fouchier RAM, Yamayoshi S, Kawaoka Y. Antigenic change in human influenza A(H2N2) viruses detected by using human plasma from aged and younger adult individuals. Viruses 11(11): 978, 2019. (OCT 2019)
  5. Feldmann F, Kobasa D, Embury-Hyatt C, Grolla A, Taylor T, Kiso M, Kakugawa S, Gren J, Jones SM, Kawaoka Y, Feldmann H. Oseltamivir is effective against 1918 influenza virus infection of macaques but vulnerable to escape. mBio 10: e02059-19, 2019. (OCT 2019)
  6. Furusawa Y, Yamada S, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bekel H, Kawaoka Y. Influenza virus polymerase mutation stabilizes a foreign gene inserted into the virus genome by enhancing the transcription/replication efficiency of the nodified segment. mBio 10: e01794-19, 2019. (OCT 2019)
  7. Sakai-Tagawa Y, Yamayoshi S, Kawaoka Y. Sensitivity of commercially available influenza rapid diagnostic tests in the 2018-2019 influenza season. Front Microbiol 10: 2342, 2019. (OCT 2019)
  8. Ujie M, Takada K, Kiso M, Sakai-Tagawa Y, Ito M, Nakamura K, Watanabe S, Imai M, Kawaoka Y. Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses. J Gen Virol 100: 1345-1349, 2019. (OCT 2019)縲€
  9. Yamada S, Yasuhara A, Kawaoka Y. Soluble recombinant hemagglutinin protein of H1N1pdm09 influenza virus elicits cross-protection against a lethal H5N1 challenge in mice. Front Microbiol 10: 2031, 2019. (SEP 2019)縲€
  10. Feng H, Nakajima N, Wu L, Yamashita M, Lopes TJS, Tsuji M, Hasegawa H, Watanabe T, Kawaoka Y. A glycolipid adjuvant, 7DW8-5, enhances the protective immune response to the current split influenza vaccine in mice. Front Microbiol 10: 2157, 2019. (SEP 2019)縲€
  11. Feng H, Yamashita M, Wu L, Lopes TJS, Watanabe T, Kawaoka Y. Food additives as novel influenza vaccine adjuvants. Vaccines 7: 127, 2019. (SEP 2019)縲€
  12. Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C. Low polymerase activity attributed to PA drives the acquisition of the PB2 E627K mutation of H7N9 avian influenza virus in mammals. MBio 10: e01162-19, 2019. (JUN 2019)
  13. Zhong G, Fan S, Lopes TJS, Le MQ, van Bakel H, Dutta J, Smith GJD, Jayakumar J, Nguyen HLK, Hoang PVM, Halfmann P, Hatta M, Su YCF, Neumann G, Kawaoka Y. Isolation of highly pathogenic H5N1 influenza viruses in 2009-2013 in vietnam. Front Microbiol 10: 1411, 2019. (JUN 2019)
  14. Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y. Subclade 2.2.1-specific human monoclonal antibodies that recognize an epitope in antigenic site A of influenza A(H5) virus HA detected between 2015 and 2018. Viruses 11: E321, 2019. (APR 2019)
  15. Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Nat Microbiol 4: 1268-1273, 2019. (APR 2019)
  16. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nat Microbiol 4:1024-1034, 2019. (MAR 2019)
  17. Oishi K, Yamayoshi S, Kawaoka Y. Identification of amino acid residues in influenza A virus PA-X That contribute to enhanced shutoff activity. Front Microbiol 10: 432, 2019. (MAR 2019)
  18. Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y. Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Euro Surveill 24: 1800467, 2019. (FEB 2019)
  19. Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y. Viruses. Characterization of mouse monoclonal antibodies against the HA of A(H7N9) influenza virus. Viruses 11: E149, 2019. (FEB 2019)
  20. Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y. Injectable excipients as novel influenza vaccine adjuvants. Front Microbiol 10: 19, 2019. (JAN 2019)
  21. Gu C, Zeng X, Song Y, Li Y, Liu L, Kawaoka Y, Zhao D, Chen H. Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses. Sci China Life Sci 62: 76-83, 2019. (JAN 2019)

2018

  1. Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. J Clin Virol 108: 105-111, 2018. (NOV 2018)
  2. Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Isolation and characterization of human monoclonal antibodies that recognize the influenza A(H1N1)pdm09 virus hemagglutinin receptor-binding site and rarely yield escape mutant viruses. Front Microbiol 9: 2660, 2018. (NOV 2018)
  3. Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y. Effectiveness of whole, inactivated, low pathogenicity influenza A(H7N9) vaccine against antigenically distinct, highly pathogenic H7N9 virus. Emerg Infect Dis 24:1910-1913, 2018. (OCT 2018)
  4. Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y. The cellular DExD/H-Box RNA helicase UAP56 co-localizes with the influenza A virus NS1 protein. Front Microbiol 9: 2192, 2018. (SEP 2018)
  5. Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA. Recurring and adaptable binding motifs in broadly neutralizing antibodies to influenza virus are encoded on the D3-9 segment of the Ig gene. Cell Host Microbe 24: 569-578, 2018. (OCT 2018)
  6. Imai H, Dinis JM, Zhong G, Moncla LH, Lopes TJS, McBride R, Thompson AJ, Peng W, Le MTQ, Hanson A, Lauck M, Sakai-Tagawa Y, Yamada S, Eggenberger J, O'Connor DH, Suzuki Y, Hatta M, Paulson JC, Neumann G, Friedrich TC, Kawaoka Y. Diversity of influenza A(H5N1) Viruses in infected humans, Northern Vietnam, 2004-2010. Emerg Infect Dis 24: 1128-1238, 2018. (JUL 2018)
  7. Ueki H, Wang IH, Fukuyama S, Katsura H, da Silva Lopes TJ, Neumann G, Kawaoka Y. In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs. Proc Natl Acad Sci U S A 115: E6622-E6629, 2018. (JUL 2018)
  8. Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y. N-terminal acetylation by NatB is required for the shutoff activity of influenza A virus PA-X. Cell Rep 24(4): 851-860, 2018. (JUL 2018)
  9. Furusawa Y, Yamada S, Kawaoka Y. Host factor nucleoporin 93 is involved in the nuclear export of influenza virus RNA. Front Microbiol 9: 1675, 2018. (JUL 2018)
  10. Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y. Development of an influenza rapid diagnostic kit specific for the H7 subtype. Front Microbiol 9: 1346, 2018. (JUN 2018)
  11. Sammaibashi S, Yamayoshi S, Kawaoka Y. Strain-specific contribution of eukaryotic elongation factor 1 gamma to the translation of influenza A virus proteins. Front Microbiol 9: 1446, 2018. (JUN 2018)
  12. Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y. The marmoset as an animal model of influenza: infection with A(H1N1)pdm09 and highly pathogenic A(H5N1) viruses via the conventional or tracheal spray route. Front Microbiol 9: 844, 2018. (MAY 2018)
  13. Matsui K, Ozawa M, Kiso M, Yamashita M, Maekawa T, Kubota M, Sugano S, Kawaoka Y. Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. Sci Rep 8: 4631, 2018. (MAR 2018)
  14. Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y. Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. J Vet Med Sci 80: 1020-1024, 2018. (JUN 2018)
  15. Maemura T, Fukuyama S, Sugita Y, Lopes TJS, Nakao T, Noda T, Kawaoka Y. Lung-derived exosomal miR-483-3p regulates the innate immune response to influenza virus infection. J Infect Dis 217: 1372-1382, 2018. (APR 2018)
  16. Yamayoshi S, Kiso M, Yasuhara A, Ito M, Shu Y, Kawaoka Y. Enhanced replication of highly pathogenic influenza A(H7N9) virus in humans. Emerg Infect Dis 24: 746-750, 2018. (APR 2018)
  17. Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Lops TJS, Ito M, Fukuyama S, Hasegawa H, Kawaoka Y. Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route. Sci Rep 8: 4801, 2018. (MAR 2018)
  18. Kiso M, Lopes TJS, Yamayoshi S, Ito M, Yamashita M, Nakajima N, Hasegawa H, Neumann G, Kawaoka Y. Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus. J Infect Dis 217: 887-896, 2018. (MAR 2018)
  19. Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, Kawaoka Y. Syrian hamster as an animal model for the study of human influenza virus infection. J Virol 92: e01693-17, 2018. (JAN 2018)
  20. Zhong G, Le MQ, Lopes TJS, Halfmann P, Hatta M, Fan S, Neumann G, Kawaoka Y. Mutations in the PA protein of avian H5N1 influenza viruses affect polymerase activity and mouse virulence. J Virol 92: e01557-17, 2018. (JAN 2018)
  21. Yamayoshi S, Ito M, Uraki R, Sasaki T, Ikuta K, Kawaoka Y. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. J Infect, in press. J Infect 76: 177-185, 2018. (FEB 2018)
  22. Oishi K, Yamayoshi S, Kawaoka Y. Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast. Virology 516: 71-75, 2018. (JAN 2018)
  23. Hatta M, Zhong G, Gao Y, Nakajima N, Fan S, Chiba S, Deering KM, Ito M, Imai M, Kiso M, Nakatsu S, Lopes TJ, Thompson AJ, McBride R, Suarez DL, Macken CA, Sugita S, Neumann G, Hasegawa H, Paulson JC, Toohey-Kurth KL, Kawaoka Y. Characterization of a feline influenza A(H7N2) virus. Emerg Infect Dis 24: 75-86, 2018. (JAN 2018)

2017

  1. Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y. Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Sci Rep 7: 17735, 2017. (DEC 2017)
  2. Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Paulson JC, Hasegawa H, Kawaoka Y. Characterization of a highly pathogenic avian H7N9 influenza virus isolated from an infected human. Cell Host&Microbe 22: 615-626, 2017. (NOV 2017)
  3. Sakai-Tagawa Y, Yamayoshi S, Kawakami C, Le MQ, Uchida Y, Saito T, Nidom CA, Humaira I, Toohey-Kurth K, Arafa AS, Liu MT, Shu Y, Kawaoka Y. Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan. Sci Rep 7: 14483, 2017. (NOV 2017)
  4. Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y. Emergence of oseltamivir-resistant H7N9 influenza viruses in immunosuppressed cynomolgus macaques. J Infect Dis 216: 582-593, 2017. (SEP 2017)
  5. Ui H, Yamayoshi S, Uraki R, Kiso M, Oishi K, Murakami S, Mimori S, Kawaoka Y. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. Vaccine 35: 1892-1897, 2017. (APR 2017)
  6. Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y. A Broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits influenza A virus particle release. EBioMedicine 17: 182-191, 2017. (MAR 2017)
  7. Zhao D, Liang L, Wang S, Nakao T, Li Y, Liu L, Guan Y, Fukuyama S, Bu Z, Kawaoka Y, Chen H. Glycosylation of the HA protein of H5N1 influenza virus increases its virulence in mice by exacerbating the host immune response. J Virol 91: e02215-02216, 2017. (MAR 2017)
  8. Nakayama M, Itoh Y, Shichinohe S, Nakabayashi R, Ishigaki H, Sakoda Y, Le QM, Kawaoka Y, Kida H, Ogasawara K. Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus. Vaccine 35: 1008-1017, 2017. (FEB 2017)

2016

  1. Arafa A-S, Yamada S, Imai M, Watanabe T, Yamayoshi S, Iwatsuki-Horimoto K, Kiso M, Sakai-Tagawa Y, Ito M, Imamura T, Nakajima N, Takahashi K, Zhao D, Oishi K, Yasuhara A, Macken C, Zhong G, Hanson A, Fan S, Ping J, Hatta M, Lopes T, Suzuki Y, El-Husseiny M, Selim A, Hagag N, Soliman M, Neumann G, Hasegawa H, Kawaoka Y. Risk assessment of recent Egyptian H5N1 influenza viruses. Sci Rep 6:38388, 2016. (DEC 6, 2016・・/li>
  2. Ando T, Yamayoshi S, Tomita Y, Watanabe S, Watanabe T, Kawaoka Y. The host protein CLUH participates in the subnuclear transport of influenza virus ribonucleoprotein complexes. Nat Microbiol 1:16062, 2016. (AUG 2016)
  3. Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov A, Kelso A, McCauley J, Wang D, Shu Y, OdagiriT, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol 1:16058, 2016. (JUN 2016)
  4. Moncla LH, Zhong G, Nelson CW, Dinis JM, Mutschler J, Hughes AL, Watanabe T, Kawaoka Y, Friedrich TC. Selective bottlenecks shape evolutionary pathways taken during mammalian adaptation of a 1918-like avian influenza virus. Cell Host Microbe 19:169-180, 2016. (FEB 10, 2016)
  5. Katsura H, Fukuyama S, Watanabe S, Ozawa M, Neumann G, Kawaoka Y. Amino acid changes in PB2 and HA affect the growth of a recombinant influenza virus expressing a fluorescent reporter protein. Sci Rep 6:19933,縲€2016. (FEB 5, 2016)
  6. Yang H, Chen Y, Qiao C, He X, Zhou H, Sun Y, Yin H, Meng S, Liu L, Zhang Q, Kong H, Gu C, Li C, Bu Z, Kawaoka Y, Chen H. Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. Proc Natl Acad Sci USA 113:392-397, 2016. (JAN 2016)
  7. Yamayoshi S, Watanabe M, Goto H, Kawaoka Y. Identification of A Novel Viral Protein Expressed from the PB2 Segment of Influenza A Virus. J Virol 90:444-456, 2016. (JAN 2016)

2015

  1. Hanson A, Imai M, Hatta M, McBride R, Imai H, Taft A, Zhong G, Watanabe T, Suzuki Y, Neumann G, Paulson JC, Kawaoka Y. Identification of Stabilizing Mutations in an H5 HA Influenza Virus Protein. J Virol 90:2981-2992, 2015. (DEC 30, 2015)
  2. Zhao D, Fukuyama S, Sakai-Tagawa Y, Takashita E, Shoemaker JE, Kawaoka Y. C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, attenuates influenza A virus infection. Antimicrob Agents Chemother 60:1902-1906, 2015. (DEC 28, 2015)
  3. Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis 212:1939-1948, 2015. (DEC 15, 2015)
  4. Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis縲€212(12):1939-1948, 2015. (DEC 15, 2015)
  5. Forero A, Tisoncik-Go J, Watanabe T, Zhong G, Hatta M, Tchitchek N, Selinger C, Chang J, Barker K, Morrison J, Berndt JD, Moon RT, Josset L, Kawaoka Y, Katze MG. The 1918 PB2 protein enhances virulence through the disruption of inflammatory and Wnt-mediated signaling in mice. J Virol 90:2240-2253, 2015. (DEC 09, 2015)
  6. Zhao D, Fukuyama S, Yamada S, Lopes TJ, Maemura T, Katsura H, Ozawa M, Watanabe S, Neumann G, Kawaoka Y. Molecular determinants of virulence and stability of a reporter-expressing H5N1 influenza A virus. J Virol 89:11337-11346, 2015. (NOV 2015)
  7. Ping J, Lopes T.J.S, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher EA, Neumann G, Kawaoka Y. Development of high-yield influenza A virus vaccine viruses. Nat Commun 6:8148, 2015. (SEP 2015・・/li>
  8. Oishi K, Yamayoshi S, Kawaoka Y. Mapping of a region of the PA-X protein of influenza A virus that is important for its shut-off activity. J Virol 89:8661-8665, 2015. (AUG 2015)
  9. Shoemaker JE, Fukuyama S, Eisfeld AJ, Zhao D, Kawakami E, Sakabe S, Maemura T, Gorai T, Katsura H, Muramoto Y, Watanabe S, Watanabe T, Fuji K, Matsuoka Y, Kitano H, Kawaoka Y. An ultrasensitive mechanism regulates influenza virus-induced inflammation. PLoS Pathog e1004856, 2015. (JUN 2015)
  10. Taft AS, Ozawa M, Fitch A, Depasse JV, Halfmann PJ, Hill-Batorski L, Hatta M, Friedrich TC, Lopes TJS, Maher EA, Ghedin E, Macken CA, Neumann B, Kawaoka Y. Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. Nat Commun 6:7491, 2015. (JUN 2015)
  11. Yamaji R, Yamada S, Le MQ, Li C, Chen H, Qurnianingsih E, Nidom CA, Ito M, Sakai-Tagawa Y, Kawaoka Y. Identification of PB2 mutations responsible for the efficient replication of H5N1 influenza viruses in human lung epithelial cells. J Virol 89:3947-3956, 2015. (APR 2015)
  12. Yamaji R, Yamada S, Le MQ, Ito M, Sakai-Tagawa Y, Kawaoka Y. Mammalian adaptive mutations of the PA protein of highly pathogenic avian H5N1 influenza virus. J Virol 89:4117-4125, 2015. (APR 2015)
  13. Fukuyama S, Katsura H, Zhao D, Ozawa M, Ando T, Shoemaker JE, Ishikawa I, Yamada S, Neumann G, Watanabe S, Kitano H, Kawaoka Y. Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies. Nat Commun, 6:6600, 2015.(MAR 2015)
  14. Yamayoshi S, Fukuyama S, Yamada S, Zhao D, Murakami S, Uraki R, Watanabe T, Tomita Y, Neumann G, Kawaoka Y. Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. Sci Rep 5:8039, 2015. (JAN 27, 2015)

2014

  1. Sakai-Tagawa Y, Ozawa M, Yamada S, Uchida Y, Saito T, Takahashi K, Sugaya N, Tashiro M, Kawaoka Y. Detection sensitivity of influenza rapid diagnostic tests. Microbiol Immunol 58:600-606, 2014.
  2. Fan S, Hatta M, Kim JH, Halfmann P, Imai M, Macken CA, Le MQ, Nguyen T, Neumann G, Kawaoka Y. Novel residues in avian influenza virus PB2 protein affect virulence in mammalian hosts. Nat Commun 5:5021, 2014.
  3. Fan S, Hatta M, Kim JH, Le MQ, Neumann G, Kawaoka Y. Amino Acid Changes in the Influenza A Virus PA Protein That Attenuate Avian H5N1 Viruses in Mammals. J Virol 88:13737-13746, 2014.
  4. Watanabe T, Zhong G, Russell CA, Nakajima N, Hatta M, Hanson A, McBride R, Burke DF, Takahashi K, Fukuyama S, Tomita Y, Maher A, Watanabe S, Imai M, Neumann G, Hasegawa H, Paulson JC, Smith DJ, Kawaoka Y. Circulating avian influenza viruses closely related to the 1918 virus have pandemic potential. Cell Host&Microbe 15:692-705, 2014.
  5. Muramoto Y, Shoemaker JE, Le MQ, Itoh Y, Tamura D, Sakai-Tagawa Y, Imai H, Uraki R, Takano R, Kawakami E, Ito M, Okamoto K, Ishigaki H, Mimuro H, Sasakawa C, Matsuoka Y, Noda T, Fukuyama S, Ogasawara K, Kitano H, Kawaoka Y. Disease Severity Is Associated with Differential Gene Expression at the Early and Late Phases of Infection in Nonhuman Primates Infected with Different H5N1 Highly Pathogenic Avian Influenza Viruses. J Virol 88:8981-8997, 2014.
  6. Itoh Y, Yoshida R, Shichinohe S, Higuchi M, Ishigaki H, Nakayama M, Pham VL, Ishida H, Kitano M, Arikata M, Kitagawa N, Mitsuishi Y, Ogasawara K, Tsuchiya H, Hiono T, Okamatsu M, Sakoda Y, Kida H, Ito M, Quynh Mai L, Kawaoka Y, Miyamoto H, Ishijima M, Igarashi M, Suzuki Y, Takada A. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. PLoS Pathog. 10:e1004192, 2014.
  7. Uraki R, Das SC, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M, Coban C, Ishii KJ, Kawaoka Y. Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine 32:5295-300, 2014.
  8. Liu Z, Kato A, Shindo K, Noda T, Sagara H, Kawaoka Y, Arii J, Kawaguchi Y. Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34 and Us3, and regulates viral nuclear egress. J Virol 88:4657-4667, 2014.
  9. Neumann G, Macken CA, Kawaoka Y. Identification of amino acid changes that may have been critical for the genesis of A(H7N9) influenza viruses. J Virol 88:4877-4896, 2014.
  10. Yamayoshi S, Yamada S, Fukuyama S, Murakami S, Zhao D, Uraki R, Watanabe T, Tomita Y, Macken C, Neumann G, Kawaoka Y. Virulence-affecting amino acid changes in the PA protein of H7N9 influenza A viruses. J Virol 88:3127-3134, 2014.

2013

  1. Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, Arikata M, Pham VL, Ishida H, Kitagawa N, Okamatsu M, Sakoda Y, Ichikawa T, Tsuchiya H, Nakamura S, Le QM, Ito M, Kawaoka Y, Kida H, Ogasawara K. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine. PLoS One 8:e82740, 2013.
  2. Wilker PR, Dinis JM, Starrett G, Imai M, Hatta M, Nelson CW, O窶僂onnor DH, Hughes AL, Neumann G, Kawaoka Y, Friedrich TC. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. Nat Commun 4:2636, 2013.
  3. Imai M, Herfst S, Sorrell EM, Schrauwen EJ, Linster M, De Graaf M, Fouchier RA, Kawaoka Y. Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178: 15-20, 2013.
  4. Takahashi T, Song J, Suzuki T, Kawaoka Y. Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic. PLoS One 8:e64439, 2013.
  5. Deng G, Tan D, Shi J, Cui P, Jiang Y, Liu L, Tian G, Kawaoka Y, Li C, Chen H. Complex reassortment of multiple subtypes of avian influenza viruses in domestic ducks at the Dongting Lake region of China. J Virol 87:9452-9462, 2013.
  6. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555, 2013.
  7. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, Kadowaki A, Ohto T, Nakanishi H, Taguchi R, Nakaya T, Murakami M, Yoneda Y, Arai H, Kawaoka Y, Penninger JM, Arita M, Imai Y. The lipid mediator protectin d1 inhibits influenza virus replication and improves severe influenza. Cell 153:112-125, 2013.
  8. Kiso M, Takano R, Sakabe S, Katsura H, Shinya K, Uraki R, Watanabe S, Saito H, Toba M, Kohda N, Kawaoka Y. Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Sci Rep 3:1563, 2013.
  9. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 18(15), 2013.
  10. Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87:7874-7881, 2013.
  11. Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep 3:1106, 2013.
  12. Fan S, Macken CA, Li C, Ozawa M, Goto H, Iswahyudi, Nidom CA, Chen H, Neumann G, Kawaoka Y. Synergistic effect of the PDZ and the p85ﾎｲ-binding domains of the NS1 protein in virulence of an avian H5N1 influenza A virus. J Virol 87:4861-4871, 2013.
  13. Watanabe T, Tisoncik-Go J, Tchitchek N, Watanabe S, Benecke AG, Katze MG, Kawaoka Y. 1918 HA and the viral RNA polymerase complex enhance viral pathogenicity, but only HA induces aberrant host responses in mice. J Virol 87:5239-5254, 2013.
  14. Uraki R, Kiso M, Shinya K, Goto H, Takano R, Iwatsuki-Horimoto K, Takahashi K, Daniels RS, Hungnes O, Watanabe T, Kawaoka Y. Virulence determinants of pandemic A(H1N1)2009 virus in a mouse model. J Virol 87:2226-2233, 2013.
  15. Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y. Identification of novel influenza A virus proteins translated from PA mRNA. J Virol 87:2344-2362, 2013.
  16. Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le MT, Iwatsuki-Horimoto K, Kawaoka Y. Differences in cytokine production in human macrophages and in virulence in mice are attributable to the acidic polymerase protein of highly pathogenic influenza A virus subtype H5N1. J Infect Dis 207: 262-271, 2013.
  17. Takano R, Kiso M, Igarashi M, Le QM, Sekijima M, Ito K, Takada A, Kawaoka Y. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the NA of H5N1 avian influenza viruses. J Infect Dis 207: 89-97, 2013.

2012

  1. Takahashi T, Nidom CA, Quynh Le MT, Suzuki T, Kawaoka Y. Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase. FEBS Open Bio 2:261-265, 2012.
  2. Shoemaker JE, Fukuyama S, Eisfeld AJ, Muramoto Y, Watanabe S, Watanabe T, Matsuoka Y, Kitano H, Kawaoka Y. Integrated network analysis reveals a novel role for the cell cycle in 2009 pandemic influenza virus-induced inflammation in macaque lungs. BMC Syst Biol 6:117, 2012.
  3. Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y. Nanoemulsion W(80)5EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 30:6871-6877, 2012.
  4. Imai M, Watanabe S, Kawaoka Y. The cytoplasmic tail domain of influenza B virus hemagglutinin is important for its incorporation into virions but is not essential for virus replication in cell culture in the presence of compensatory mutations. J Virol 86:11633-11644, 2012.
  5. Shimojima M, Kawaoka Y. Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus gycoprotein. J Vet Med Sci 74:1363-1366, 2012.
  6. Shimojima M, Stroher U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol 86: 2067-2078, 2012.
  7. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 86: 4123-4128, 2012.
  8. Nidom CA, Yamada S, Nidom RV, Rahmawati K, Alamudi MY, Kholik, Indrasari S, Hayati RS, Iwatsuki Horimoto K, Kawaoka Y. Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010. Virus Genes 44: 459-465, 2012.
  9. Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, Deng G, Zhu Q, Fan S, Makino A, Muramoto Y, Fukuyama S, Tamura D, Noda T, Eisfeld AJ, Katze MG, Chen H, Kawaoka Y. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol 86: 6055-6066, 2012.
  10. Kikuchi T, Iwatsuki-Horimoto K, Adachi E, Koga M, Nakamura H, Hosoya N, Kawana-Tachikawa A, Koibuchi T, Miura T, Fujii T, Kawaoka Y, Iwamoto A. Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults. Vaccine 30: 3819-3823, 2012.
  11. Watanabe T, Imai M, Watanabe S, Shinya K, Hatta M, Li C, Neumann G, Ozawa M, Hanson A, Zhong G, Fukuyama S, Kawakami E, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Kilander A, Dudman SG, Suresh M, Hungnes O, Friedrich TC, Kawaoka Y. Characterization in vitro and in vivo of pandemic (H1N1) 2009 viruses isolated from patients. J Virol 86: 9361-9368, 2012.
  12. Zhang Y, Zhang Q, Gao Y, He X, Kong H, Jiang Y, Guan Y, Xia X, Shu Y, Kawaoka Y, Bu Z, Chen H. Key molecular factors in HA and PB2 contribute to the efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol 86: 9666-9674, 2012.
  13. Inagaki A, Goto H, Kakugawa S, Ozawa M, Kawaoka Y. Competitive incorporation of homologous gene segments of influenza A virus into virions. J Virol 86: 10200-10202, 2012.
  14. Yamada S, Shinya K, Takada A, Ito T, Suzuki T, Suzuki Y, Me QM, Ebina M, Kasai N, Kida H, Horimoto T, Rivailler P, Chen LM, Donis RO, Kawaoka Y. Adaptation of a duck influenza A virus in quail. J Virol 86:1411-1420, 2012.
  15. Das SC, Watanabe S, Hatta M, Noda T, Neumann G, Ozawa M, Kawaoka Y. The highly conserved arginine residues at positions 76 through 78 of influenza A virus matrix protein M1 play an important role in viral replication by affecting the intracellular localization of M1. J Virol 86:1522-1530, 2012.
  16. Shi J, Wen Z, Guo J, Zhang Y, Deng G, Shu Y, Wang D, Jiang Y, Kawaoka Y, Bu Z, Chen H. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice. Antiviral Res 93:346-353, 2012.
  17. Noda T, Sugita Y, Aoyama K, Hirose A, Kawakami E, Miyazawa A, Sagara H, Kawaoka Y. Three-dimensional analysis of ribonucleoprotein complexes in influenza A virus. Nat Commun 3:639, 2012.
  18. Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, Kawaoka Y. Amino acid changes in hemagglutinin contribute to the replication of osertamivir-resistant H1N1 influenza viruses. J Virol 86:121-127, 2012.
  19. Shinya K, Ito M, Makino A, Tanaka M, Miyake K, Eisfeld AJ, Kawaoka Y. The TLR4-TRIF pathway protects against H5N1 influenza virus infection. J Virol 86:19-24, 2012.
  20. Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, Kawaoka Y. Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion. J Virol 86:1405-1410, 2012.

2011

  1. Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol 85:10989-10998, 2011.
  2. Watanabe T, Shinya K, Watanabe S, Imai M, Hatta M, Li C, Wolter BF, Neumann G, Hanson A, Ozawa M, Yamada S, Imai H, Sakabe S, Takano R, Iwatsuki-Horimoto K, Kiso M, Ito M, Fukuyama S, Kawakami E, Gorai T, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Nishio W, Maniwa Y, Igarashi T, Makino A, Travanty EA, Wang J, Kilander A, Dudman SG, Suresh M, Mason RJ, Hungnes O, Friedrich TC, Kawaoka Y. Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaques. J Virol 85:13195-13203, 2011.
  3. Octaviani CP, Goto H, Kawaoka Y. Reassortment between seasonal H1N1 and pandemic (H1N1) 2009 influenza viruses is restricted by limited compatibility among polymerase subunits. J Virol 85:8449-8452, 2011.
  4. Horimoto T, Maeda K, Murakami S, Kiso M, Iwatsuki-Horimoto K, Sashika M, Ito T, Suzuki K, Yokoyama M, Kawaoka Y. Highly pathogenic avian influenza virus infection in feral raccoons, Japan. Emerging Infectious Diseases 17:714-717, 2011.
  5. Shimizu K, Li C, Muramoto Y, Yamada S, Arikawa J, Chen H, Kawaoka Y. The NP and M segments of H5N1 influenza viruses are responsible for dominance in embryonated eggs. J Gen Virol 92:1645-1649, 2011.
  6. Shinya K, Makino A, Tanaka H, Hatta M, Watanabe T, Le MQ, Imai H, Kawaoka Y. Systemic dissemination of H5N1 influenza A viruses in ferrets and hamsters after direct intragastric inoculation. J Virol 85:4673-4678, 2011.
  7. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Hatta Y, Gao P, Ozawa M, Le QM, Kawaoka Y. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol 85:5202-5207, 2011.
  8. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J 8:97, 2011.
  9. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le MT, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol 92:1428-1434, 2011.
  10. Kiso M, Ozawa M, Le MT, Imai H, Takahashi K, Kakugawa S, Noda T, Horimoto T, Kawaoka Y. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol 85:4667-4672, 2011.
  11. Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S, Ebihara Y, Koibuchi T, Fujii T, Takahashi K, Shimojima M, Sakai-Tagawa Y, Ito M, Sakabe S, Iwasa A, Takahashi K, Ishii T, Gorai T, Tsuji K, Iwamoto A, Kawaoka Y. Sero-prevalence of pandemic (H1N1) 2009 Influenza A Virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol 18:860-866, 2011.
  12. Ozawa M, Basnet S, Burley LM, Neumann G, Hatta M, Kawaoka Y. Impact of amino acid mutations in PB2, PB1-F2, and NS1 on the replication and pathogenicity of pandemic (H1N1) 2009 influenza viruses. J Virol 85:4596-5601, 2011.
  13. Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, Kawakami C, Shimizu H, Uehara R, Kiso M, Kawakami E, Mitamura K, Kawaoka Y. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 52:432-437, 2011.
  14. Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults. Vaccine 29:9224-9228, 2011.
  15. Ozawa M, Victor ST, Taft AS, Yamada S, Li C, Hatta M, Das SC, Takashita E, Kakugawa S, Maher EA, Neumann G, Kawaoka Y. Replication-incompetent influenza A viruses that stably express a foreign gene. J Gen Virol 92(Pt 12):2879-2888, 2011.
  16. Sakabe S, Ozawa M, Takano R, Iwatsuki-Horimoto K, Kawaoka Y. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res 158:124-129, 2011.
  17. Yamaoka M, Palilingan JF, Wibisono J, Yudhawati R, Nidom RV, Alamudi MY, Ginting TE, Makino A, Nidom CA, Shinya K, Kawaoka Y. Virological surveillance of human influenza in Indonesia, October 2008-March 2010. Microbiol Immunol 55:514-517, 2011.
  18. Poetranto ED, Yamaoka M, Nastri AM, Krisna LA, Rahman MH, Wulandari L, Yudhawati R, Ginting TE, Makino A, Shinya K, Kawaoka Y. An H5N1 highly pathogenic avian influenza virus isolated from a local tree sparrow in Indonesia. Microbiol Immunol 55:666-672, 2011.
  19. Song J, Feng H, Xu J, Zhao D, Shi J, Li Y, Deng G, Jiang Y, Li X, Zhu P, Guan Y, Bu Z, Kawaoka Y, Chen H. The PA protein directly contributes to the virulence of H5N1 avian influenza viruses in domestic ducks. J Virol 85:2180-2188, 2011.

2010

  1. Chen Y, Zhong G, Wang G, Deng G, Li Y, Shi J, Zhang Z, Guan Y, Jiang Y, Bu Z, Kawaoka Y, Chen H. Dogs are highly susceptible to H5N1 avian influenza virus. Virology 405:15-19, 2010.
  2. Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, Shinya K, Iwatsuki-Horimoto K, Muramoto Y, Kawaoka Y. H5N1 influenza viruses from pigs in Indonesia. Emerg Inf Dis 16:1515-1523, 2010.
  3. Le QM, Ito M, Muramoto Y, Hoang PV, Vuong CD, Sakai-Tagawa Y, Kiso M, Ozawa M, Takano R, Kawaoka Y. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans from 2003 to 2008 in Northern Vietnam. J Gen Virol 91:2485-2490, 2010.
  4. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le MQ, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88:249-255, 2010.
  5. Hatta Y, Hershberger K, Shinya K, Dubielzig RR, Hatta M, Kawaoka Y, Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathogens 6:e1001139, 2010.
  6. Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le MQ, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, NodaT, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y. The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. PLoS Pathogens 6:e1001106, 2010.
  7. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. High genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol 84:10918-10922, 2010.
  8. Yamada S, Hatta M, Staker BL, Watanabe S, Imai M, Shinya K, Sakai-Tagawa Y, Ito M, Ozawa M, Watanabe T, Sakabe S, Li C, Kim JH, Myler PJ, Phan I, Raymond A, Smith E, Stacy R, Nidom CA, Lank SM, Wiseman RW, Bimber BN, O窶僂onnor DH, Neumann G, Stewart LJ, Kawaoka Y. Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathogens 6:e1001034, 2010
  9. Sakai-Tagawa Y, Ozawa M, Tamura D, Le QM, Nidom CA, Sugaya N, Kawaoka Y. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol 48:2872-2877, 2010.
  10. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Kawaoka Y. A mutation in H5 haemagglutinin that conferred human receptor recognition is not maintained stably during duck passage. J Gen Virol 91:1461-1463, 2010.
  11. Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G, Kawaoka Y. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence Proc Natl Acad Sci USA 107:4687-4692, 2010.
  12. Kim JH, Hatta M, Watanabe S, Neumann G, Watanabe T, Kawaoka Y. Role of host-specific amino acids in the pathogenicity of avian H5N1 influenza viruses in mice J Gen Virol 91:1284-1289, 2010.
  13. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, Kawaoka Y. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses Plos Patho 6: e1000786, 2010.
  14. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses Proc Natl Acad Sci USA 107:882-887, 2010.

2009

  1. Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Taong T, Zhong G, Song J, Zhang Y, Tian G, Guan Y, Xu X-N, Bu Z, Kawaoka Y, Chen H Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates Plos Patho 5:e1000409, 2009.
  2. Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, Li Z, Guan Y, Tian G, Li Y, Shi J, Liu L, Zeng X, Bu Z, Xia X, Kawaoka Y, Chen H. Identification of Amino Acids in HA and PB2 Critical for the Transmission of H5N1 Avian Influenza Viruses in a Mammalian Host Plos Patho 5:e1000709, 2009.
  3. Shinya K, Makino A, Ozawa M, Kim JH, Sakai-Tagawa Y, Ito M, Le QM, Kawaoka Y. Ostrich involvement in the selection of H5N1 influenza virus possessing mammalian-type amino acids in PB2 J Virol 83:13015-13018, 2009.
  4. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Meumann G, Gern J, Kida H, Ogawsawara K & Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025, 2009.
  5. Takano R, Nidom CA, Kiso M, Muramoto Y, Yamada S, Shinya K, Sakai-Tagawa Y, Kawaoka Y. A comparison of the pathogenicity of avian and swine H5N1 influenza viruses in Indonesia. Arch Virol 154:677-681, 2009.
  6. Watanabe S, Watanabe T, Kawaoka Y Influenza A virus lacking M2 protein as a live attenuated vaccine J Virol 83:5947-5950, 2009.
  7. Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, Neumann G, Feldmann H, Kawaoka Y. Replication-Deficient Ebolavirus as a Vaccine Candidate. J Virol 83:3810-3815, 2009.
  8. Li Z, Watanabe T, Hatta M, Watanabe S, Nanbo A, Ozawa M, Kakugawa S, Shimojima M, Yamada S, Neumann G, Kawaoka Y. Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. J Virol 83:4153-4162, 2009.
  9. Le QM, Sakai-Tagawa Y, Ozawa M, Ito M, Kawaoka Y. Selection of H5N1 influenza virus PB2 during replication in human J Virol 83:5278-5281, 2009.
  10. Fan S, Deng G, Song J, Tian G, Suo Y, Jiang Y, Guan Y, Bu Z, Kawaoka Y, Chen H. Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice Virology 384:28-32, 2009.

2008

  1. Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y. Compatibility among polymerase subunit proteins is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses J virol 82:11880-11888, 2008.
  2. Jia B, Shi J, Li Y, Shinya K, Muramoto Y, Zeng X, Tian G, Kawaoka Y, Chen H. Pathogenicity of Chinese H5N1 highly pathogenic avian influenza viruses in pigeons. Arch Virol 153:1821-1826, 2008.
  3. Murakami S, Iwasa A, Iwatasuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Midon CA, Mai LQ, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26:6398-6404, 2008.
  4. Murakami S, Horimoto T, Mai LQ, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. Journal of Virology 82:10502-10509, 2008.
  5. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454:890-893, 2008.
  6. Iwatsuki-Horimoto K, Hatta Y, Hatta M, Muramoto Y, Chen H, Kawaoka Y, Horimoto T. Limited compatibility between the RNA polymerase components of influenza virus type A and B Virus Res 135:161-165, 2008.
  7. Jiao P, Tian G, Li Y, Liu C, Liu W, Deng G, Guan Y, Bu Z, Kawaoka Y, Chen H. A single amino acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice Journal of Virology 82:1146-1154, 2008.
  8. Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol 82:1605-1609, 2008.
  9. Zhu Q, Yang H, Deng G, Yu K, Bu Z, Kawaoka Y, Chen H. A naturally occurring deletion in its NS gene contributes to attenuation of an H5N1 swine influenza virus in chickens. Journal of Virology 82:220-228, 2008.

2007

  1. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Kawaoka Y. Growth of H5N1 influenza A viruses in the upper resporatory tracts of mice. Plos Pathogens 3: 1374-1379, 2007.

2006

  1. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, HorimotoT, Shinya K, Sawada T, Kiso M, Usui T, Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel JJ, Kawaoka Y. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382, 2006.
  2. Chen H, Li Y, Li Z, Shi J, Shinya K, Deng G, Qi Q, Tian G, Fan S, Zhao H, Sun Y, Kawaoka Y. Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. Journal of Virology:80, 5976-5983, 2006.
  3. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Influenza virus receptors in the human airway. Nature 440:435-436, 2006.

2005

  1. Le QM, Kiso M, Someya K, Sakai YT, NguyenTH, Nguyen KHL, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. Emergence of an oseltamivir-resistant H5N1 influenza A virus. Nature 437:1108, 2005.
・・a href="../index_e.html">Home・・a href="../aboutus/index_e.html">About Us・・a href="../ibpcas/index_e.html">Institute of Biophysics・・a href="../imcas/index_e.html">Institute of Microbiology・・a href="../hvri/index_e.html">Harbin Veterinary Research Institute・・a href="../sitemap_e.html">Sitemap・・/div>